HK1231410A1 - 作為 抑制劑的二環雜環衍生物 - Google Patents
作為 抑制劑的二環雜環衍生物Info
- Publication number
- HK1231410A1 HK1231410A1 HK17105239.1A HK17105239A HK1231410A1 HK 1231410 A1 HK1231410 A1 HK 1231410A1 HK 17105239 A HK17105239 A HK 17105239A HK 1231410 A1 HK1231410 A1 HK 1231410A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- irak4
- bicyclic heterocyclyl
- inhibitors
- heterocyclyl derivatives
- derivatives
- Prior art date
Links
- 229940127590 IRAK4 inhibitor Drugs 0.000 title 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN158CH2014 | 2014-01-13 | ||
IN3000CH2014 | 2014-06-20 | ||
PCT/IB2015/050217 WO2015104688A1 (en) | 2014-01-13 | 2015-01-12 | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1231410A1 true HK1231410A1 (zh) | 2017-12-22 |
Family
ID=53523587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK17105239.1A HK1231410A1 (zh) | 2014-01-13 | 2017-05-24 | 作為 抑制劑的二環雜環衍生物 |
Country Status (31)
Country | Link |
---|---|
US (6) | US9732095B2 (zh) |
EP (4) | EP3094329B1 (zh) |
JP (5) | JP6479850B2 (zh) |
KR (3) | KR102392684B1 (zh) |
CN (2) | CN111362966B (zh) |
AU (5) | AU2015205374B2 (zh) |
BR (1) | BR112016016158B1 (zh) |
CA (1) | CA2935887A1 (zh) |
CU (1) | CU24389B1 (zh) |
CY (2) | CY1121433T1 (zh) |
DK (3) | DK3805233T3 (zh) |
EA (2) | EA031913B1 (zh) |
ES (2) | ES2692852T3 (zh) |
FI (1) | FI3805233T3 (zh) |
HK (1) | HK1231410A1 (zh) |
HR (2) | HRP20181795T1 (zh) |
HU (2) | HUE052252T2 (zh) |
IL (6) | IL302878B1 (zh) |
LT (3) | LT3805233T (zh) |
MX (1) | MX359909B (zh) |
MY (1) | MY197116A (zh) |
NZ (2) | NZ722019A (zh) |
PH (2) | PH12016501344A1 (zh) |
PL (2) | PL3466955T3 (zh) |
PT (3) | PT3805233T (zh) |
RS (2) | RS61448B1 (zh) |
SG (2) | SG11201605486WA (zh) |
SI (2) | SI3466955T1 (zh) |
TR (1) | TR201815683T4 (zh) |
WO (1) | WO2015104688A1 (zh) |
ZA (2) | ZA202007273B (zh) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
US10160753B2 (en) | 2014-01-10 | 2018-12-25 | Aurigene Discovery Technologies Limited | Indazole compounds as IRAK4 inhibitors |
LT3805233T (lt) | 2014-01-13 | 2024-05-10 | Aurigene Oncology Limited | N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui |
EA201890308A1 (ru) * | 2015-07-15 | 2018-08-31 | Ориджин Дискавери Текнолоджиз Лимитед | Замещенные азасоединения как ингибиторы irak-4 |
EP3719016A1 (en) | 2015-08-04 | 2020-10-07 | Rigel Pharmaceuticals, Inc. | Benzazole compounds and methods for making and using the compounds |
WO2017148902A1 (de) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
PT3600270T (pt) * | 2017-03-31 | 2023-07-25 | Aurigene Discovery Tech Ltd | Compostos e composições para tratar distúrbios hematológicos |
EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES OF THE LATEST |
IL273432B (en) | 2017-09-22 | 2022-09-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
IL308364A (en) | 2017-10-31 | 2024-01-01 | Curis Inc | Compounds and preparations for the treatment of hematological disorders |
US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
SG11202005912PA (en) | 2017-12-26 | 2020-07-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
EP3305786A3 (de) | 2018-01-22 | 2018-07-25 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
AU2019220632B2 (en) | 2018-02-14 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | IRAK degraders and uses thereof |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
KR102612513B1 (ko) | 2018-07-31 | 2023-12-12 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
EP3911652A1 (en) * | 2019-01-18 | 2021-11-24 | Biogen MA Inc. | Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors |
EP3998264A4 (en) * | 2019-07-10 | 2023-07-12 | Medshine Discovery Inc. | OXAZOLE COMPOUND AS A MULTI-TARGETED INHIBITOR OF IRAK4 AND BTK |
WO2021016289A1 (en) * | 2019-07-23 | 2021-01-28 | Bristol-Myers Squibb Company | Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors |
JP7386576B2 (ja) | 2019-10-02 | 2023-11-27 | カイノス・メディスン・インコーポレイテッド | N-(1h-イミダゾール-2-イル)ベンズアミド化合物および該化合物を活性成分として含む医薬組成物 |
EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
BR112022011651A2 (pt) | 2019-12-17 | 2022-08-23 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
WO2021198980A1 (en) | 2020-04-04 | 2021-10-07 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
BR112022019987A2 (pt) | 2020-04-07 | 2022-11-22 | Bayer Ag | Tiazolpiridinas substituídas, seus sais e uso dos mesmos como substâncias herbicidamente ativas |
EP4142717A4 (en) * | 2020-04-28 | 2024-05-29 | Kymera Therapeutics Inc | IRAQ INHIBITORS AND USES THEREOF |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
MX2023001296A (es) * | 2020-08-03 | 2023-02-22 | Curis Inc | Composiciones y metodos para tratar enfermedades y trastornos. |
EP4237423A1 (en) | 2020-11-02 | 2023-09-06 | Boehringer Ingelheim International GmbH | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
JP2024500247A (ja) * | 2020-12-25 | 2024-01-05 | メッドシャイン ディスカバリー インコーポレイテッド | アミドオキサゾール系化合物 |
TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
CN117177965B (zh) * | 2021-12-23 | 2024-04-30 | 杭州多域生物技术有限公司 | 一种五元并六元化合物、制备方法、药物组合物和应用 |
TW202330546A (zh) * | 2021-12-31 | 2023-08-01 | 香港商愛科諾生物醫藥(香港)有限公司 | 具有irak4抑制活性的化合物,包含其的藥物組合物,及其應用 |
WO2024081893A1 (en) * | 2022-10-13 | 2024-04-18 | Kymera Therapeutics, Inc. | Salt forms of irak4 degraders |
WO2024092011A1 (en) * | 2022-10-25 | 2024-05-02 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9008022A (pt) | 1990-05-18 | 1993-04-06 | Hoechst Ag | Amida de acido isoxazol-4-carboxilico e amidas de acido hidroxialquilideno-cianoacetico,medicamentos contendo estes compostos e sua aplicacao |
DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
EP1581539A4 (en) * | 2003-01-03 | 2007-09-19 | Bristol Myers Squibb Co | NEW TYROSINE KINASE HEMMER |
WO2004096310A2 (en) | 2003-04-25 | 2004-11-11 | Cook, Inc. | Low friction coated marked wire guide for over the wire insertion of a catheter |
BRPI0409949A (pt) | 2003-05-01 | 2006-04-25 | Bristol Myers Squibb Co | compostos de pirazol amida aril-substituìda úteis como inibidores de cinase |
EP2281823A3 (en) | 2003-05-20 | 2011-09-07 | Ajinomoto Co., Inc. | Anti-inflammatory and analgesic piperidine derivatives |
JP2006526660A (ja) | 2003-06-05 | 2006-11-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Vr1レセプターのモジュレーター |
EP1493795A1 (de) | 2003-07-04 | 2005-01-05 | Collano AG | Klebstoffzusammensetzung |
US7338950B2 (en) | 2003-10-07 | 2008-03-04 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
MXPA06012104A (es) | 2004-04-22 | 2007-01-25 | Bayer Cropscience Lp | Metodo y composicion para controlar malas hierbas. |
EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
US7696202B2 (en) | 2004-11-10 | 2010-04-13 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
SI1828177T1 (sl) | 2004-12-17 | 2009-02-28 | Lilly Co Eli | Novi antagonisti mch receptorja |
BRPI0519124A2 (pt) | 2004-12-17 | 2008-12-23 | Lilly Co Eli | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço |
EP1674467A1 (en) | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
CN102633783A (zh) | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
MX2008012482A (es) | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
WO2007121154A2 (en) | 2006-04-11 | 2007-10-25 | Janssen Pharmaceutica, N.V. | Substituted benzothiazole kinase inhibitors |
EP2063962A2 (en) | 2006-09-07 | 2009-06-03 | Biogen Idec MA Inc. | Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
JP2010502717A (ja) | 2006-09-07 | 2010-01-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | インターロイキン1受容体関連キナーゼの調節物質 |
WO2008061109A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
CN101679297B (zh) | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | Lxr和fxr调节剂 |
JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
AR066958A1 (es) | 2007-06-14 | 2009-09-23 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
ES2457418T3 (es) | 2007-07-16 | 2014-04-25 | Abbvie Inc. | Indazoles, bencisoxazoles y bencisotiazoles como inhibidores de proteína cinasas |
MX2010001446A (es) | 2007-08-08 | 2010-03-01 | Merck Serono Sa | Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple. |
WO2009102468A1 (en) | 2008-02-13 | 2009-08-20 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof |
EP2311842A3 (en) | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
AU2009316786A1 (en) | 2008-11-19 | 2010-05-27 | Merck Sharp & Dohme Corp. | Inhibitors of diacylglycerol acyltransferase |
WO2010071819A1 (en) * | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
CN102264701A (zh) | 2008-12-23 | 2011-11-30 | 霍夫曼-拉罗奇有限公司 | 作为p2x7调节剂的二氢吡啶酮脲 |
WO2010144909A1 (en) | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
EP2467137A1 (en) | 2009-08-19 | 2012-06-27 | Ambit Biosciences Corporation | Biaryl compounds and methods of use thereof |
JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
CN102656141B (zh) | 2009-10-13 | 2016-04-06 | 利亘制药公司 | 模拟造血生长因子的小分子化合物及其用途 |
WO2011133750A1 (en) | 2010-04-22 | 2011-10-27 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
EP2563358A4 (en) | 2010-04-30 | 2013-09-25 | Merck Sharp & Dohme | INHIBITORS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK1) |
DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
RU2604062C2 (ru) | 2010-07-13 | 2016-12-10 | Ф.Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4 |
MX344521B (es) | 2010-11-19 | 2016-12-19 | Ligand Pharm Inc | Aminas heterociclicas y sus usos. |
SI2655357T1 (sl) | 2010-12-20 | 2016-10-28 | Merck Serono S.A. | Derivati indazolil triazola kot zaviralci IRAK |
US9320786B2 (en) | 2011-04-12 | 2016-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria |
WO2013042137A1 (en) * | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
MY167575A (en) | 2011-10-14 | 2018-09-20 | Ambit Biosciences Corp | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases |
US9957271B2 (en) | 2011-10-20 | 2018-05-01 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
WO2013066729A1 (en) * | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
KR101385603B1 (ko) | 2012-05-17 | 2014-04-21 | 한국원자력의학원 | 벤조티아졸 유도체 및 암 치료를 위한 그의 용도 |
WO2014003483A1 (en) | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
US9334249B2 (en) | 2012-11-03 | 2016-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
CA2907960C (en) | 2013-05-22 | 2021-10-19 | Children's Hospital Medical Center | Combination therapy for mds |
TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
US10160753B2 (en) | 2014-01-10 | 2018-12-25 | Aurigene Discovery Technologies Limited | Indazole compounds as IRAK4 inhibitors |
LT3805233T (lt) * | 2014-01-13 | 2024-05-10 | Aurigene Oncology Limited | N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (r) ir (s) enantiomerai, kaip irak4 inhibitoriai, skirti vėžio gydymui |
BR112016017996A2 (pt) | 2014-02-06 | 2017-08-08 | Abbvie Inc | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso |
WO2015193846A1 (en) | 2014-06-20 | 2015-12-23 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as irak4 inhibitors |
JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
US20180289685A1 (en) | 2015-04-30 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
EA201890308A1 (ru) | 2015-07-15 | 2018-08-31 | Ориджин Дискавери Текнолоджиз Лимитед | Замещенные азасоединения как ингибиторы irak-4 |
KR20180025896A (ko) | 2015-07-15 | 2018-03-09 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak-4 저해제로서 인다졸 및 아자인다졸 화합물 |
EP3719016A1 (en) | 2015-08-04 | 2020-10-07 | Rigel Pharmaceuticals, Inc. | Benzazole compounds and methods for making and using the compounds |
US20210292843A1 (en) | 2016-10-28 | 2021-09-23 | Children's Hospital Medical Center | Treatment of diseases associated with activated irak |
PT3600270T (pt) | 2017-03-31 | 2023-07-25 | Aurigene Discovery Tech Ltd | Compostos e composições para tratar distúrbios hematológicos |
IL308364A (en) | 2017-10-31 | 2024-01-01 | Curis Inc | Compounds and preparations for the treatment of hematological disorders |
US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
MX2023001296A (es) | 2020-08-03 | 2023-02-22 | Curis Inc | Composiciones y metodos para tratar enfermedades y trastornos. |
IL302869A (en) | 2020-11-18 | 2023-07-01 | Curis Inc | Methods of treating diseases and disorders |
IL307465A (en) | 2021-04-08 | 2023-12-01 | Curis Inc | Combined therapies for cancer treatment |
WO2023220227A1 (en) | 2022-05-11 | 2023-11-16 | Curis, Inc. | Treating diseases and disorders with irak4-modifying compounds |
-
2015
- 2015-01-12 LT LTEP20211096.1T patent/LT3805233T/lt unknown
- 2015-01-12 PL PL18190333T patent/PL3466955T3/pl unknown
- 2015-01-12 SG SG11201605486WA patent/SG11201605486WA/en unknown
- 2015-01-12 JP JP2016563278A patent/JP6479850B2/ja active Active
- 2015-01-12 MX MX2016009013A patent/MX359909B/es active IP Right Grant
- 2015-01-12 KR KR1020167021713A patent/KR102392684B1/ko active IP Right Grant
- 2015-01-12 SG SG10201811204RA patent/SG10201811204RA/en unknown
- 2015-01-12 IL IL302878A patent/IL302878B1/en unknown
- 2015-01-12 AU AU2015205374A patent/AU2015205374B2/en active Active
- 2015-01-12 DK DK20211096.1T patent/DK3805233T3/da active
- 2015-01-12 EP EP15735499.4A patent/EP3094329B1/en active Active
- 2015-01-12 PT PT202110961T patent/PT3805233T/pt unknown
- 2015-01-12 FI FIEP20211096.1T patent/FI3805233T3/fi active
- 2015-01-12 NZ NZ722019A patent/NZ722019A/en unknown
- 2015-01-12 HU HUE18190333A patent/HUE052252T2/hu unknown
- 2015-01-12 KR KR1020237029626A patent/KR20230129622A/ko not_active Application Discontinuation
- 2015-01-12 KR KR1020227014075A patent/KR102574390B1/ko active IP Right Grant
- 2015-01-12 PT PT15735499T patent/PT3094329T/pt unknown
- 2015-01-12 ES ES15735499.4T patent/ES2692852T3/es active Active
- 2015-01-12 MY MYPI2021007377A patent/MY197116A/en unknown
- 2015-01-12 EP EP18190333.7A patent/EP3466955B1/en active Active
- 2015-01-12 RS RS20210039A patent/RS61448B1/sr unknown
- 2015-01-12 SI SI201531483T patent/SI3466955T1/sl unknown
- 2015-01-12 DK DK15735499.4T patent/DK3094329T3/en active
- 2015-01-12 LT LTEP18190333.7T patent/LT3466955T/lt unknown
- 2015-01-12 LT LTEP15735499.4T patent/LT3094329T/lt unknown
- 2015-01-12 TR TR2018/15683T patent/TR201815683T4/tr unknown
- 2015-01-12 CN CN202010147212.8A patent/CN111362966B/zh active Active
- 2015-01-12 IL IL311677A patent/IL311677A/en unknown
- 2015-01-12 DK DK18190333.7T patent/DK3466955T3/da active
- 2015-01-12 EP EP20211096.1A patent/EP3805233B1/en active Active
- 2015-01-12 CA CA2935887A patent/CA2935887A1/en active Pending
- 2015-01-12 SI SI201530477T patent/SI3094329T1/sl unknown
- 2015-01-12 CN CN201580013752.4A patent/CN106456619B/zh active Active
- 2015-01-12 BR BR112016016158-0A patent/BR112016016158B1/pt active IP Right Grant
- 2015-01-12 RS RS20181355A patent/RS58024B1/sr unknown
- 2015-01-12 NZ NZ760657A patent/NZ760657A/en unknown
- 2015-01-12 EA EA201691428A patent/EA031913B1/ru unknown
- 2015-01-12 CU CU2016000111A patent/CU24389B1/es unknown
- 2015-01-12 PT PT181903337T patent/PT3466955T/pt unknown
- 2015-01-12 PL PL15735499T patent/PL3094329T3/pl unknown
- 2015-01-12 WO PCT/IB2015/050217 patent/WO2015104688A1/en active Application Filing
- 2015-01-12 US US15/111,000 patent/US9732095B2/en active Active
- 2015-01-12 EP EP23214923.7A patent/EP4353324A2/en active Pending
- 2015-01-12 ES ES18190333T patent/ES2846678T3/es active Active
- 2015-01-12 IL IL284952A patent/IL284952B/en unknown
- 2015-01-12 EA EA201891917A patent/EA038748B1/ru unknown
- 2015-01-12 HU HUE15735499A patent/HUE041926T2/hu unknown
- 2015-01-12 IL IL294895A patent/IL294895B2/en unknown
-
2016
- 2016-07-03 IL IL246575A patent/IL246575B/en active IP Right Grant
- 2016-07-07 PH PH12016501344A patent/PH12016501344A1/en unknown
-
2017
- 2017-05-24 HK HK17105239.1A patent/HK1231410A1/zh unknown
- 2017-08-02 US US15/667,173 patent/US10047104B2/en active Active
-
2018
- 2018-08-03 US US16/054,512 patent/US10640517B2/en active Active
- 2018-10-30 HR HRP20181795TT patent/HRP20181795T1/hr unknown
- 2018-11-20 AU AU2018267569A patent/AU2018267569B2/en active Active
- 2018-12-21 CY CY20181101382T patent/CY1121433T1/el unknown
-
2019
- 2019-02-06 JP JP2019019229A patent/JP6750053B2/ja active Active
- 2019-12-11 IL IL271364A patent/IL271364B/en unknown
- 2019-12-17 AU AU2019283795A patent/AU2019283795B2/en active Active
-
2020
- 2020-02-19 US US16/795,394 patent/US10995100B2/en active Active
- 2020-03-13 PH PH12020500529A patent/PH12020500529A1/en unknown
- 2020-06-25 JP JP2020109507A patent/JP6977111B2/ja active Active
- 2020-11-23 ZA ZA2020/07273A patent/ZA202007273B/en unknown
- 2020-11-23 ZA ZA2020/07274A patent/ZA202007274B/en unknown
-
2021
- 2021-01-19 HR HRP20210094TT patent/HRP20210094T1/hr unknown
- 2021-01-29 CY CY20211100076T patent/CY1123936T1/el unknown
- 2021-04-30 US US17/245,611 patent/US11691987B2/en active Active
- 2021-06-08 AU AU2021203761A patent/AU2021203761B2/en active Active
- 2021-11-10 JP JP2021183016A patent/JP7262553B2/ja active Active
-
2023
- 2023-04-11 JP JP2023063800A patent/JP2023085526A/ja active Pending
- 2023-04-28 US US18/141,008 patent/US11981685B2/en active Active
- 2023-09-01 AU AU2023222987A patent/AU2023222987A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284952A (en) | History of bicyclic heterocyclyls as IRAK4 inhibitors | |
HRP20181650T1 (hr) | Biciklički heterociklički derivati kao inhibitori bromodomene | |
AP2016009371A0 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
HK1226398A1 (zh) | 作為midh1抑制劑的苯並咪唑-2-胺 | |
IL252866A0 (en) | History of imidazopyridazine as pi3kbeta inhibitors | |
SI3097076T1 (sl) | Novi derivati CYP-eikozanoida | |
IL252868A0 (en) | History of heterocyclyl-related imidazopyridazines as pi3kbeta inhibitors | |
GB201416351D0 (en) | Heterocyclic derivatives |